## **Synthesis of Phantasmidine†**

## **Quan Zhou and Barry B. Snider\***

*Department of Chemistry MS 015, Brandeis Uni*V*ersity, Waltham, Massachusetts 02454-9110, United States*

*snider@brandeis.edu*

**Received December 3, 2010**



**ABSTRACT**

**Reaction of 6-chloro-2-fluoro-3-pyridineacetamide with 1,2-bis(trimethylsilyloxy)cyclobutene in ether saturated with hydrogen chloride afforded the keto amide in 85% yield. In the key step, treatment of the keto amide with aqueous KOH in** *t***-BuOH resulted in a tandem intramolecular aldol reaction**-**intramolecular nucleophilic aromatic substitution sequence to give the tetracylic lactam in 46% yield. Reduction of the lactam** with BH<sub>3</sub> in THF gave phantasmidine in 67% yield.

The biological properties<sup>1</sup> and chemical synthesis<sup>2</sup> of the potent nicotinic agonist epibatidine (**2**) (see Scheme 1) have been intensively studied since it was isolated from the skin of the Ecuadorian poison frog *Epipedobates anthonyi* and characterized in 1992 by Daly and co-workers. Fitch, Daly, and co-workers recently isolated phantasmidine (**1**), a rigid tetracyclic congener of epibatidine from the same source.<sup>3</sup> The structure of phantasmidine was tentatively assigned from a combination of GC-MS and GC-FTIR analysis with oncolumn derivatization and 1D and 2D NMR spectroscopy of HPLC-purified **1** and its acetamide with a total sample of only ∼20 *µ*g. Preliminary biological studies with the limited material available indicated that phantasmidine (**1**) differs from epibatidine (2) by being selective for  $\beta$ 4-containing



2 (epibatidine)

**Scheme 1.** Retrosynthesis of Phantasmidine (**1**)

1 (phantasmidine)



<sup>†</sup> Dedicated to the late Dr. John W. Daly of NIDKK, NIH, Bethesda, Maryland for his pioneering work on biologically active natural products.

 $(1)$  (a) Daly, J. W.; Garraffo, H. M.; Spande, T. F.; Decker, M. W.; Sullivan, J. P.; Williams, M. *Nat. Prod. Rep.* **2000**, *17*, 131–135. (b) Carroll, F. I. *Biorg. Med. Chem. Lett.* **2004**, *14*, 1889–1896. (c) Daly, J. W. *Cell. Mol. Neurobiol.* **2005**, *25*, 513–552. (d) Garraffo, H. M.; Spande, T. F.; Williams, M. *Heterocycles* **2009**, *79*, 207–218.

<sup>(2)</sup> Olivio, H. F.; Hemenway, M. S. *Org. Prep. Proc. Int.* **2002**, *34*, 1–26, and references cited therein.

<sup>(3)</sup> Fitch, R. W.; Spande, T. F.; Garraffo, H. M.; Yeh, H. J. C.; Daly, J. W. *J. Nat. Prod.* **2010**, *73*, 331–337.

nicotinic receptors suggesting that phantasmidine might fill a niche for characterization of these receptors. However, the limited natural material available precluded detailed pharmacological analysis and definitive structure determination. We therefore undertook the synthesis of phantasmidine (**1**).

We thought that phantasmidine (**1**) should be readily available by reduction of lactam **3**. In the key step of the proposed synthesis we planned to prepare lactam **3** from keto amide **<sup>5</sup>** by a novel tandem intramolecular aldol reactionintramolecular nucleophilic aromatic substitution sequence. Addition of the amide enolate of **5** to the cyclobutanone carbonyl group should provide alkoxide **4**, which should undergo a nucleophilic aromatic substitution reaction<sup>4</sup> at the activated 2-halopyridine to form the furan ring of **3**. Although two stereoisomeric aldol products can be formed, the alkoxide can displace the halide only in **4**. The aldol reaction is reversible so the two isomers should be in equilibrium with the reaction driven to completion by the cyclization of the desired stereoisomer **4** to give lactam **3**. Keto amide **5** should be readily available by the reaction of primary amide **6** with 1,2-bis(trimethylsilyloxy)cyclobutene (**7**), the readily available acyloin formed from succinate esters, in ether saturated with hydrogen chloride by the literature procedure.<sup>5</sup> We chose to start with the more readily available, but less reactive, dichloroamide **6a**. Schlosser has shown that nucleophilic substitution of a 2-fluoropyridine is ∼320 times faster than substitution of a 2-chloropyridine.<sup>6</sup> The use of fluorochloroamide **6b** therefore offered an attractive alternative if nucleophilic aromatic substitution of dichloropyridine **4a** to form the furan ring of **3** failed.

Commercially available 2,6-dichloropyridine-3-carboxaldehyde  $(8a)^7$  was reduced with NaBH<sub>4</sub> in MeOH at 0 °C for 30 min to give primary alcohol **9a**<sup>8</sup> in 99% yield (see Scheme 2). Reaction with thionyl chloride and catalytic DMF in  $CH_2Cl_2$  at 25 °C for 6 h gave chloride  $10a$ <sup>9</sup>, which was treated with NaCN in aqueous EtOH at reflux for 4 h to give nitrile 11a<sup>9</sup> in 64% yield from alcohol 9a. Hydrolysis<sup>10</sup> of nitrile **11a** with methanesulfonic acid and alumina at 120

D. P. *Synth. Commun.* **2008**, *38*, 1679–1687. (6) Schlosser, M.; Rausis, T. *Hel*V*. Chim. Acta* **<sup>2005</sup>**, *<sup>88</sup>*, 1240–1249. (7) Aldehyde **8a** can be easily prepared by metalation of 2,6-dichloropyridine with LDA at the 3-position and addition of DMF. See: Radinov,

R.; Chanev, C.; Haimova, M. *J. Org. Chem.* **1991**, *56*, 4793–4796. (8) (a) Newkome, G. R.; Lee, H.-W. *J. Org. Chem.* **1982**, *47*, 2800– 2802. (b) Leonard, K.; Marugan, J. J.; Raboisson, P.; Calvo, R.; Gushue, J. M.; Koblish, H. K.; Lattanze, J.; Zhao, S.; Cummings, M. D.; Player, M. R.; Maroney, A. C.; Lu, T. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 3463–

3468.<br>(9) (a) Horn, U.; Mutterer, F.; Weis, C. D. *Helv. Chim. Acta* 1976, 59, (9) (a) Horn, U.; Mutterer, F.; Weis, C. D. *Hel*V*. Chim. Acta* **<sup>1976</sup>**, *<sup>59</sup>*, 190–211. (b) Lieb, F.; Hagemann, H.; Widdig, A.; Ruther, M.; Fischer, R.; Bretschneider, T.; Erdelen, C.; Wachendorff-Neumann, U.; Graff, A.; Dahmen, P.; Dollinger, M.; Gallenkamp, B. Ger. Pat. 1997, DE 19651841; *Chem. Abstr.* **1997**, *128*, 22816. (c) Bailly, J.; Hertel, C.; Hunziker, D.; Lerner, C.; Obst Sander, U.; Peters, J.-U.; Pflieger, P.; Schulz-Gasch, T. PCT Int. Appl. 2009, WO 2009040288 A1; *Chem. Abstr.* **2009**, *150*, 374301. (d) Cordingley, M. R.; Turnbull, M. D.; Carter, N. B.; Crowley, P. J. PCT Int. Appl. 2009, WO 2009090402 A2; *Chem. Abstr.* **2009**, *151*, 165630. (10) Sharghi, H.; Sarvari, M. H. *Synth. Commun.* **2003**, *33*, 207–212.





°C for 15 min afforded the requisite dichloroamide **6a** in 70% yield. Reaction of primary amide **6a** with 1,2-bis(trimethylsilyloxy)cyclobutene (**7**) in ether saturated with hydrogen chloride in a sealed tube at 80 °C for 2 h afforded cyclobutanone amide **5a** in 78% yield.<sup>5</sup>

Unfortunately all attempts to convert keto amide **5a** to tetracyclic lactam **3** were unsuccessful. For instance, treatment of **5a** with aqueous potassium hydroxide in *t*-BuOH gave a complex mixture of products. Based on limited literature precedent, $11$  we thought that acylation of the amide would not only remove the acidic NH proton, but would also facilitate enolization and the intramolecular aldol reaction because the  $\alpha$ -protons of an imide are more acidic than those of an amide. Treatment of  $5a$  with  $(Boc)<sub>2</sub>O$ , NEt<sub>3</sub>, and DMAP in  $CH_2Cl_2$  at 25 °C acylated the amide to give imide **12**, which underwent the desired aldol reaction to give alkoxide **13**. Unfortunately, nucleophilic aromatic substitution with displacement of the chloride was sufficiently slow so that only the unstable  $\alpha$ ,  $\beta$ -unsaturated lactam **14** resulting from dehydration of the aldol product was isolated in 61% yield. Since we were unable to form the furan ring of phantasmidine from dichloropyridine **5a**, we turned our attention to the preparation of the more reactive chlorofluoropyridine **5b**.

Metalation of 2-choro-6-fluoropyridine (**15**) adjacent to the fluoride with LDA in THF at  $-78$  °C by the literature

<sup>(4)</sup> An intramolecular nucleophilic aromatic substitution to form a furan was achieved by heating 2,6-dichloro-3-(2-hydroxyphenyl)pyridine with potassium carbonate in acetonitrile at reflux for 5 h to give the benzofuropyridine in 70% yield. See: Parmentier, M.; Gros, P.; Fort, Y. *Tetrahedron* **2005**, *61*, 3261–3269.

<sup>(5) (</sup>a) Bisel, P.; Breitling, E.; Frahm, W. *Eur. J. Org. Chem.* **1998**, 729–733. (b) Lall, M. S.; Ramtohul, Y. K.; James, M. N. G.; Vederas, J. C. *J. Org. Chem.* **2002**, *67*, 1536–1547. (c) Armoush, N.; Syal, P.; Becker,

<sup>(11) (</sup>a) Jacobi, P. A.; DeSimone, R. W.; Ghosh, I.; Guo, Leung, S. H.; Pippin, D. *J. Org. Chem.* **2000**, *65*, 8478–8489. (b) Miyazaki, H.; Ogiku, T.; Sai, H.; Moritani, Y.; Ohtani, A.; Ohmizu, H. *Chem. Pharm. Bull.* **2009**, *57*, 979–985.

**Scheme 3.** Synthesis of  $(\pm)$ -Phantasmidine (1)



procedure<sup>12</sup> and trapping with DMF afforded the known aldehyde **8b**12a in 90% yield (Scheme 3). The 2-fluoropyridine is very sensitive to nucleophilic attack by the LiNMe<sub>2</sub> formed by addition of the carbanion to DMF, so the reaction was quenched by addition of saturated hydrogen chloride in ether at  $-78$  °C.<sup>13</sup> Reduction of the aldehyde of 8b with NaBH<sub>4</sub> in MeOH at  $-10$  °C gave alcohol 9b in 90% yield. Conversion of the alcohol to the chloride with thionyl chloride and catalytic DMF in  $CH<sub>2</sub>Cl<sub>2</sub>$  proceeded uneventfully to give **10b** because the reaction conditions are acidic. Substitution of the benzylic chloride without hydrolysis of the 2-fluoropyridine was best accomplished by reaction with sodium cyanide in DMSO at 25 °C for 1 h to give nitrile

(13) Schlosser, M.; Rausis, T. *Eur. J. Org. Chem.* **2004**, 1018–1024.

**11b** in 63% yield from alcohol **9b**. Hydrolysis of the nitrile to the amide with methanesulfonic acid and alumina at 120 °C for 15 min afforded fluorochloroamide **6b** in 61% yield, which was converted to keto amide **5b** in 85% yield by reaction with **7** in ether saturated with hydrogen chloride for 2 h at 80 °C in a sealed tube. The sensitivity of the 2-fluoropyridine to nucleophilic attack was not an issue in the last two reactions that were run under acidic conditions.

Fortunately, the increased reactivity of the fluoride of keto amide **5b** was sufficient to facilitate formation of the furan ring of lactam **3**. Treatment of a degassed solution of **5b** in *t*-BuOH with degassed 2 M aqueous KOH resulted in aldol cyclization to give alkoxide **4b**, which underwent the desired nucleophilic aromatic substitution reaction to form furan **3** in 46% yield. The yields were slightly lower if the solution was not carefully degassed, suggesting that the enolate is susceptible to autoxidation. The structure of **3** was readily assigned by analysis of the NMR spectra and was confirmed by X-ray crystal structure determination. No other products were isolated. This suggests that either the aldol reaction to give **4b** is stereospecific or, more likely, the aldol reaction is reversible and the undesired stereoisomer **16** reverts to **5b** which then recyclizes to give **4b** and then **3**.

Reduction of lactam **3** with borane in THF afforded the borane complex of phantasmidine which was decomplexed $14$ by treatment with piperazine to give phantasmidine (**1**) in 67% yield. Reduction of lactam **3** with alane (LAH and AlCl3) <sup>15</sup> was less successful affording phantasmidine (**1**) in  $20-30%$  yield. Addition of 1 equiv of TFA to a CD<sub>3</sub>OD solution of phantasmidine afforded the monocation, whose <sup>1</sup>H NMR spectrum is identical to that reported for natural phantasmidine•DCl.3 Pyrrolidine **1** was treated with AcCl and NEt<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> at  $-15$  to 25 °C to give acetamide 17 in 67% yield. The <sup>1</sup>H and <sup>13</sup>C NMR spectra of **17** (mixture of rotamers) are identical to those reported for the acetamide of phantasmidine.<sup>3</sup> The GC retention times of synthetic and natural phantasmidine are identical as are the mass spectra of synthetic and natural phantasmidine and phantasmidine acetamide. Therefore the synthesis of **1** validates the structure of phantasmidine assigned from the incomplete data obtained from the very limited amount (∼20 *µ*g) of natural material available.<sup>3</sup>

This synthesis leads to racemic phantasmidine. The coupling of **6b** and **7** affords racemic keto amide **5b**. However, even if we were able to prepare **5b** in enantiomerically pure form, it would likely be racemized under the very basic conditions of the tandem intramolecular aldol reaction-intramolecular nucleophilic aromatic substitution sequence. We therefore investigated the resolution of phantasmidine and found that the two enantiomers are very readily separated by chiral HPLC on a Chiralcel OJ-H column with retention times of 27 and 40 min. This facile separation makes both enantiomers readily available for full biological

investigation. (12) (a) Altman, M.; Christopher, M.; Grimm, J. B.; Haidle, A.; Konrad, K.; Lim, J.; Maccoss, R. N.; Machacek, M.; Osimboni, E.; Otte, R. D.; Siu, T.; Spencer, K.; Taoka, B.; Tempest, P.; Wilson, K.; Woo, H. C.; Young, J.; Zabierek, A. PCT Int. Appl. 2008, WO 2008156726; *Chem. Abstr.* **2008**, *150*, 77500. (b) Beutner, G. L.; Kuethe, J. T.; Kim, M. M.; Yasuda, N. *J. Org. Chem.* **2009**, *74*, 789–794.

<sup>(14) (</sup>a) Brown, H. C.; Choi, Y. M.; Narasimhan, S. *J. Org. Chem.* **1982**, *47*, 3153–3163. (b) Couturier, M.; Tucker, J. L.; Andresen, B. M.; Dube, P.; Negri, J. L. *Org. Lett.* **2001**, *3*, 465–467.

<sup>(15)</sup> Yoon, N. M.; Brown, H. C. *J. Am. Chem. Soc.* **1968**, *90*, 2927– 2938.

In conclusion, we have developed a short, efficient synthesis (8 steps, 8% overall yield) of  $(\pm)$ -phantasmidine that confirms the structure assigned from the incomplete data obtained from the very limited amount (∼20 *µ*g) of natural material available. This synthesis makes material readily available for further biological evaluation, which is currently in progress. The key step, a novel tandem intramolecular aldol reaction-intramolecular nucleophilic aromatic substitution that converts keto amide **5b** with aqueous KOH in *t*-BuOH to tetracylic lactam **3**, should be broadly useful for making phantasmidine analogues.

**Acknowledgment.** We are grateful to the National Institutes of Health (GM-50151) for support of this work. We thank the National Science Foundation for partial support of this work through Grant CHE-0521047 for the purchase of a new X-ray diffractometer. We thank Mr. Brian A. Provencher, Brandeis University, for assistance with the resolution of phantasmidine. We thank Drs. H. Martin Garraffo and Thomas F. Spande, National Institute of Diabetes, Digestive and Kidney Diseases, for comparing the GC retention times of synthetic and natural phantasmidine.

**Supporting Information Available:** Complete experimental procedures, copies of <sup>1</sup>H NMR, <sup>13</sup>C NMR, and CD spectral data, and CIF file and drawing of X-ray crystal structure of lactam **3**. This material is available free of charge via the Internet at http://pubs.acs.org.

OL102929M